Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This phase Ib/II trial studies the side effects and best dose of ibrutinib and how well it
works in treating patients with COVID-19 requiring hospitalization. Ibrutinib may help
improve COVID-19 symptoms by lessening the inflammatory response in the lungs, while
preserving overall immune function. This may reduce the need to be on a ventilator to help
with breathing.
Phase:
Phase 2
Details
Lead Sponsor:
Jennifer Woyach
Collaborators:
Janssen Scientific Affairs, LLC National Cancer Institute (NCI)